C-RAD

Transaction in Own Shares • Aug 28, 2023

Repurchase of C-RAD B-shares in week 34, 2023

During 21 August 2023 and 23 August 2023, C-RAD AB (publ) (LEI code 549300SPXLHF15W2CU25), has repurchased in total 28,500 own B-shares (ISIN: SE0002016352).

The repurchase is carried out in accordance with the Annual General Meeting's authorization to the Board to acquire shares in the Company. The purpose of the repurchase is to cover the Company's obligations under previously resolved incentive programs.

Date:	Aggregated daily volume (number of shares):	Weighted average share price per day (SEK):	Total daily transaction value (SEK):
2023- 08-21	15,000	31.0834	466,251
2023- 08-22	8,500	31.5243	267,957
2023- 08-23	5,000	31.8600	159,300
Total:	28,500	31.3511	893,508

All acquisitions have been carried out on Nasdaq Stockholm by Pareto on behalf of C-RAD. Following the above acquisitions, C-RAD AB holds a total of 88,500 class B-shares in treasury as per 23 August 2023, equivalent to 0.26 percent of the total number of shares outstanding, and 0.21 percent of the votes. The total number of shares outstanding in C-RAD AB, including shares held in treasury, is 33,766,935, where of 862,887 are Class A-shares and 32,904,048 are Class B-shares.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com Press Release 28 August 2023 10:00:00 CEST

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

Attachments

Repurchase of C-RAD B-shares in week 34, 2023